Why Stocks Fell After Jobs Report
Last Friday, the Bureau of Labor Statistics posted non-farm payrolls. The U.S. economy created a slower rate of job growth. Still, the healthy labor market will deter the Federal Reserve from cutting interest rates.In January, the economy added 143,000 jobs. Investors should factor in the BLS revising job growth in November and December 2024 up by 100,000 jobs.The Dow, Nasdaq (QQQ), and S&P 500 (IVV) all closed lower on the day in response. Markets needed the hope of rate cuts to continue their rally. The bond market traded mostly flat, as the 7-10 Year Treasury Bond ETF (IEF) found support at $93.14.RisksInvestors should not read much into the healthy 4.0% unemployment rate. Full-time jobs could be replaced with part-time jobs, which paints a less robust job market. For example, Uber (UBER) and DoorDash (DASH) are counted the same as full-time jobs.The Trump Administration acted quickly to pause hiring in the Federal government. Job cuts started and will only accelerate in the coming weeks. Though government job cuts will hurt future NFP reports, expect spending in healthcare and the military to continue.Shares of UnitedHealth (UNH), Cigna (CI), and Elevance (ELV) all priced in moderate healthcare spending this year. In the military sector, Lockheed Martin (LMT) is trading at 28% below its 52-week high, closing at $444.39. L3Harris (LHX) is 3% above its 52-week low.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


